Search results for " Mutation"

showing 10 items of 1212 documents

Evolution of lactase persistence: an example of human niche construction

2011

Niche construction is the process by which organisms construct important components of their local environment in ways that introduce novel selection pressures. Lactase persistence is one of the clearest examples of niche construction in humans. Lactase is the enzyme responsible for the digestion of the milk sugar lactose and its production decreases after the weaning phase in most mammals, including most humans. Some humans, however, continue to produce lactase throughout adulthood, a trait known as lactase persistence. In European populations, a single mutation (−13910*T) explains the distribution of the phenotype, whereas several mutations are associated with it in Africa and the Middle …

Adult0106 biological sciencesAsiaNatural selectionmedicine.medical_treatmentLactoseBiology010603 evolutionary biology01 natural sciencesGene Expression Regulation EnzymologicGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesGene FrequencyLactase persistencemedicineAnimalsHumansComputer SimulationNeolithicAlleleDomesticationLactaseddc:599.9030304 developmental biology2. Zero hungerGenetics0303 health sciencesGenetic VariationLactaseArticlesBiological EvolutionEuropeDomestic animalsDairyingLactase persistenceNiche constructionGenetics PopulationMilkAfricaTraitLocal environmentCattleNiche constructionGeneral Agricultural and Biological SciencesSingle mutationPhilosophical Transactions of the Royal Society B: Biological Sciences
researchProduct

Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation

2020

Background Hereditary angioedema (HAE) is a potentially fatal disorder resulting in recurrent attacks of severe swelling. It may be associated with a genetic deficiency of functional C1 inhibitor or with normal C1 inhibitor (HAEnCI). In families with HAEnCI, HAE-linked mutations in the F12, PLG, KNG1, ANGPT1, or MYOF genes have been identified. In many families with HAEnCI the genetic cause of the disease is currently unknown. Objective The aim of this study was to identify a novel disease-linked mutation for HAEnCI. Methods The study methods comprised whole exome sequencing, Sanger sequencing analysis, pedigree analysis, bioinformatic analysis of the mutation, and biochemical analysis of p…

Adult0301 basic medicineImmunologyMutantGene mutationBiologyC1-inhibitor03 medical and health sciencessymbols.namesakechemistry.chemical_compound0302 clinical medicineExome SequencingmedicineHumansImmunology and AllergyExome sequencingAged 80 and overSanger sequencingGeneticsAngioedemas HereditaryHeparan sulfateMiddle Agedmedicine.disease030104 developmental biology030228 respiratory systemchemistryMutationMutation (genetic algorithm)Hereditary angioedemasymbolsbiology.proteinFemaleSulfotransferasesJournal of Allergy and Clinical Immunology
researchProduct

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

2018

Purpose This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. A unicenter translational substudy assessed potential mechanisms of lurbinectedin resistance. Patients and Methods Two arms were evaluated according to germline BRCA1/2 status: BRCA1/2 mutated (arm A; n = 54) and unselected ( BRCA1/2 wild-type or unknown status; arm B; n = 35). Lurbinectedin starting dose was a 7-mg flat dose and later, 3.5 mg/m2 in arm A. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST). The translational substudy of resist…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGenes BRCA2Genes BRCA1Phases of clinical researchAntineoplastic AgentsBreast NeoplasmsHeterocyclic Compounds 4 or More RingsMice03 medical and health sciences0302 clinical medicineGermline mutationInternal medicineBiomarkers TumorClinical endpointAnimalsHumansMedicineProgression-free survivalGerm-Line MutationAgedDose-Response Relationship DrugErratabusiness.industryMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysMetastatic breast cancerProgression-Free SurvivalClinical trial030104 developmental biologyOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisBiomarker (medicine)FemalebusinessCarbolinesJournal of Clinical Oncology
researchProduct

Influence of LDL receptor gene mutations and the R3500Q mutation of the apoB gene on lipoprotein phenotype of familial hypercholesterolemic patients …

2003

Few data are available on genotype-phenotype interactions among familial hypercholesterolemia (FH) patients in South European populations and there are no data about the influence of R3500Q mutation on lipoprotein phenotype compared to low-density lipoprotein receptor (LDLR) mutations. The objective of the study is to analyze the influence of mutations in the LDLR and apolipoprotein B (apoB) genes on lipoprotein phenotype among subjects clinically diagnosed of FH living in East Spain. In all, 113 FH index patients and 100 affected relatives were studied. Genetic diagnosis was carried out following a protocol based on Southern blot and PCR-SSCP analysis. A total of 118 FH subjects could be c…

AdultAdolescentApolipoprotein BHypercholesterolemiaPopulationMutation MissenseFamilial hypercholesterolemiaBiologymedicine.disease_causechemistry.chemical_compoundGeneticsmedicineHumansMissense mutationeducationGenetics (clinical)Apolipoproteins BGeneticsMutationeducation.field_of_studyCholesterolMiddle Agedmedicine.diseaseEuropePhenotypeReceptors LDLchemistryLDL receptorbiology.proteinlipids (amino acids peptides and proteins)LipoproteinEuropean Journal of Human Genetics
researchProduct

Havep53 gene mutations and protein expression a different biological significance in colorectal cancer?

2002

p53 alterations are considered the most common genetic events in many types of neoplasms, including colorectal carcinoma (CRC). These alterations include mutations of the gene and/or overexpression of the protein. The aim of our study was to assess whether in 160 patients undergoing resective surgery for primary operable CRC there was an association between p53 mutations and protein over-expression and between these and other biological variables, such as cell DNA content (DNA-ploidy) and S-phase fraction (SPF), and the traditional clinicopathological variables. p53 mutations, identified by PCR-SSCP-sequencing analysis, were found in 68/160 patients (43%) and positive staining for p53 prote…

AdultAged 80 and overMaleBase SequenceDNA Mutational AnalysisP53 colorectal cancerDNAMiddle AgedGenes p53ImmunohistochemistryProtein Structure TertiaryGene Expression Regulation NeoplasticMutationHumansFemaleGenetic TestingProspective StudiesIntestinal MucosaTumor Suppressor Protein p53Colorectal NeoplasmsAged
researchProduct

Mutational analysis of 105 mucopolysaccharidosis type VI patients

2007

Mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome) is a lysosomal storage disorder caused by mutations in the N-acetylgalactosamine-4-sulfatase (arylsulfatase B, ARSB) gene. ARSB is a lysosomal enzyme involved in the degradation of the glycosaminoglycans (GAG) dermatan and chondroitin sulfate. ARSB mutations reduce enzyme function and GAG degradation, causing lysosomal storage and urinary excretion of these partially degraded substrates. Disease onset and rate of progression is variable, producing a spectrum of clinical presentation. In this study, 105 MPS VI patients—representing about 10% of the world MPS VI population—were studied for molecular genetic and biochemical parame…

AdultArylsulfatase BAdolescentN-Acetylgalactosamine-4-SulfataseMPS VIDNA Mutational AnalysisNonsense mutationMucopolysaccharidosis type VIBiologyPolymorphism Single NucleotideGenetic HeterogeneityAge DistributionGene FrequencyGenotypeGeneticsmedicineHumansMissense mutationGenetic TestingChildCells CulturedGenetics (clinical)mucopolysaccharidosis type VIGlycosaminoglycansGeneticsMucopolysaccharidosis VIGenetic heterogeneityMucopolysaccharidosis VIMiddle Agedmedicine.diseasearylsulfatase BMaroteaux–Lamy syndromeDisease ProgressionARSBMaroteaux-LamyHuman Mutation
researchProduct

Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene

2013

International audience; Fanconi anaemia (FA) is characterized by progressive bone marrow failure, congenital anomalies, and predisposition to malignancy. In a minority of cases, FA results from biallelic FANCD1/BRCA2 mutations that are associated with early-onset leukaemia and solid tumours. Here, we describe the clinical and molecular features of a remarkable family presenting with multiple primary colorectal cancers (CRCs) without detectable mutations in genes involved in the Mendelian predisposition to CRCs. We unexpectedly identified, despite the absence of clinical cardinal features of FA, a biallelic mutation of the FANCD1/BRCA2 corresponding to a frameshift alteration (c.1845_1846del…

AdultBiallelic MutationRNA Splicing[SDV]Life Sciences [q-bio]DNA Mutational AnalysisBiologymedicine.disease_causeArticleFrameshift mutationGeneticsmedicineHumansMissense mutationAge of OnsetGeneAllelesGenetics (clinical)BRCA2 ProteinGeneticsMutationPoint mutationComputational BiologyChromosome BreakageBRCA2 ProteinPedigree3. Good healthAmino Acid SubstitutionMutationFemaleRNA Splice SitesChromosome breakageColorectal NeoplasmsEuropean Journal of Human Genetics
researchProduct

Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

2014

Abstract There is growing interest in delivering genomically informed cancer therapy. Our aim was to determine the concordance of genomic alterations between primary and recurrent breast cancer. Targeted next-generation sequencing was performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 3,320 exons of 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer. Point mutations, indels, copy-number alterations (CNA), and select rearrangements were assessed in 74 tumors from 43 patients (36 primary and 38 recurrence/metastases). Alterations potentially targetable with established or investigational therapeutics were considered “actionable.” Alterations…

AdultCancer ResearchARID1AConcordanceBreast NeoplasmsGenomicsArticleExonBreast cancermedicineCluster AnalysisHumansPTENNeoplasm MetastasisAgedNeoplasm StagingAged 80 and overbiologyGene Expression ProfilingPoint mutationGenomicsMiddle Agedmedicine.diseaseGene Expression Regulation NeoplasticGene expression profilingOncologyMutationbiology.proteinCancer researchFemaleNeoplasm Recurrence LocalMolecular Cancer Therapeutics
researchProduct

Retinoblastoma epidemiology: Does the evidence matter?

2007

It has been proposed that retinoblastoma is 'caused' by two sequential mutations affecting the RB1 gene, but this is a rather outdated view of cancer aetiology that does not take into account a large amount of new acquisitions such as chromosomal and epigenetic alterations. Retinoblastoma remains probably the only cancer in which the rather simplistic 'two hit' mutational model is still considered of value, although cancer is known to be associated with genomic and microsatellite instability, defects of the DNA mismatch repair system, alterations of DNA methylation and hystone acethylation/deacethylation, and aneuploidy. Moreover, as it is shown herein, the predictions made by the 'two hit'…

AdultCancer ResearchAdolescentRetinal NeoplasmsRetinoblastoma Aneuploidy Two hit theoryDiseaseBiologyAge DistributionChromosome instabilitymedicineHumansEpigeneticsAge of OnsetChildGerm-Line MutationGeneticsRetinoblastomaRetinoblastomaMicrosatellite instabilityCancerInfantMiddle Agedmedicine.diseasePedigreeSettore BIO/18 - GeneticaOncologyChild PreschoolDNA methylationDNA mismatch repair
researchProduct

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

2011

Abstract The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary and matched metastatic breast tumors as this could influence patient management. Paraffin sections of 50 μm were used for DNA extraction and slides of 3 μm for immunohistochemistry (IHC) and FISH. Estrogen receptor, progesterone receptor, and HER2 IHC were repeated in a central laboratory for both primary tumors and metastases. PTEN levels were assessed by IHC and phosphoinositide 3-kinase (PI3K) pathway mutations were detected by a mass spectroscopy–based approach. Median age was 48 years (range: 30–83 years). Tumor subtype included 72% horm…

AdultCancer Researchmedicine.medical_specialtyClass I Phosphatidylinositol 3-KinasesReceptor ErbB-2Breast Neoplasmsmedicine.disease_causeArticleMetastasisMetastasisPhosphatidylinositol 3-KinasesBreast cancerInternal medicineBreast CancermedicinePTENHumansPTEN lossReceptorneoplasmsPI3K/AKT/mTOR pathwayAgedAged 80 and overMutationbiologyPTEN PhosphohydrolaseMiddle Agedmedicine.diseaseMetastatic breast cancerEndocrinologyOncologyReceptors EstrogenMutationbiology.proteinCancer researchImmunohistochemistryFemalePIK3CA mutationsReceptors ProgesteroneSignal TransductionMolecular cancer therapeutics
researchProduct